Tuesday, November 20, 2018 4:35:02 PM
Christina Farr | @chrissyfarr
CNBC.com
In a show of transparency, Verily posted a blog post on Friday explaining why it is hitting the pause button on its glucose-sensing contact lens.
The project was first announced in 2014, back when Verily was known as Google Life Sciences.
It will shift focus to other eye-related projects, the company said.
Google smart contact lens to measure glucose levels in tears.
Source: Google
Google smart contact lens to measure glucose levels in tears.
Verily, Alphabet's life sciences arm, has paused work on its so-called "smart lens" program, which was aiming to put tiny sensors on contact lenses to measure blood sugar levels in tears.
If it worked, the lenses could help diabetics track their glucose levels in real time and in less invasive ways than the traditional meters that require piercing the skin. But in a blog post on Friday, Verily said that after four years of research it has determined that detecting blood sugar in tears is a massive — and potentially insurmountable — technical and scientific undertaking.
"Our clinical work on the glucose-sensing lens demonstrated that there was insufficient consistency in our measurements of the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device," the company said.
Verily made a big splash when if first launched the program in 2014, while it was still known as Google Life Sciences. The company partnered with Alcon, Novartis' eye-care division, on the project. However, it's been quiet about the project in the past few years, leading to speculation that it was winding down.
Verily said it did have some success with the experiment in a controlled environment, but not in actual tests because of the dynamic environment of the eye. It's a problem that goes beyond Verily.
Recent KNW News
- Know Labs to Present Clinical Research at the 2024 American Physiology Summit • Business Wire • 04/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:10:40 PM
- Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study • Business Wire • 03/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:17:42 PM
- Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives • Business Wire • 02/29/2024 09:15:00 PM
- Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor • Business Wire • 02/27/2024 04:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 02:03:51 PM
- Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor • Business Wire • 02/27/2024 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:17:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:26 PM
- Know Labs, Inc. Reports First Quarter FY2024 Results • Business Wire • 02/14/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:23:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:22:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:20:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:19:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:18:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:17:03 PM
- Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024 • Business Wire • 02/07/2024 02:00:00 PM
- Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) • Business Wire • 01/23/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/12/2024 05:15:08 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/05/2024 09:16:39 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 09:15:52 PM
- Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 12/19/2023 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/19/2023 09:03:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM